Efficacy and Safety of 2 mg/Day M100907 on Sleep Maintenance Insomnia: a 6-week, Multicenter, Randomized, Double-blind, Placebo-controlled Polysomnographic Study

Trial Profile

Efficacy and Safety of 2 mg/Day M100907 on Sleep Maintenance Insomnia: a 6-week, Multicenter, Randomized, Double-blind, Placebo-controlled Polysomnographic Study

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Volinanserin (Primary)
  • Indications Sleep maintenance insomnia
  • Focus Therapeutic Use
  • Acronyms NOCTURNE907
  • Sponsors Sanofi
  • Most Recent Events

    • 16 Feb 2009 Actual patient number reported as 604 by ClinicalTrials.gov.
    • 16 Feb 2009 Actual end date reported as 1 Jan 2008 by ClinicalTrials.gov.
    • 16 Feb 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top